
    <html>
    <head><title>CRDL.TO</title>
<style>
body {
  font-family: Arial, sans-serif;
  margin: 20px;
}
.container {
  display: grid;
  grid-template-columns: 50% 50%;
  grid-template-rows: auto auto;
  gap: 20px;
}
img {
  width: 100%;
  height: auto;
  max-height: 400px;
  border: 1px solid #ccc;
  object-fit: contain;
}

.cell {
  padding: 10px;
}
.table-scroll {
  max-height: 400px;
  overflow-y: auto;
  border: 1px solid #aaa;
}
table {
  width: 100%;
  border-collapse: collapse;
}
th, td {
  border: 1px solid #aaa;
  padding: 5px;
  text-align: left;
  font-size: 14px;
}
.negative {
  background: linear-gradient(to right, #ffdddd, white);
}
.positive {
  background: linear-gradient(to right, white, #ddffdd);
}
.pos-light  { background: #e6ffe6; }  
.pos-mid    { background: #99ff99; }  
.pos-strong { background: #33cc33; }   

.neg-light  { background: #ffe6e6; }   
.neg-mid    { background: #ff9999; }   
.neg-strong { background: #ff3333; }   

h2 { border-bottom: 2px solid #444; }
<script>
function toggleText(id) {
  const moreText = document.getElementById(id);
  const btn = document.getElementById(id + "_btn");

  if (moreText.style.display === "none") {
    moreText.style.display = "inline";
    btn.innerText = " Show less";
  } else {
    moreText.style.display = "none";
    btn.innerText = " Show more";
  }
}
</script>
</style>
</head>
    <body>
    <h2><span style='color:#1e66f5; font-weight:900; margin-right:10px;'>quarterly earnings d</span> CRDL.TO  
        <span style='font-weight:normal; font-size: 18px;'></span>
        <span style='color:black; font-weight:bold; font-size: 20px;'> </span>
        <a href='https://finance.yahoo.com/chart/CRDL.TO?interval=1mo' target='_blank'>Yahoo</a>
        <span style='font-weight:600;'>  —  — now: 1.51</span>
    </h2>

    <div class="container">
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><div style='display:flex; gap:10px; align-items:flex-start'>  <div style='flex:0 0 50%'><a href='https://vosorin.github.io/100__2025_06_public/RAPORT/B_ZOOM_CRDL.TO_ALL.jpg' target='_blank'>    <img src='B_ZOOM_CRDL.TO_ALL.jpg' alt='B_ZOOM_CRDL.TO_ALL.jpg'></a></div>  <div style='flex:0 0 50%'><a href='https://vosorin.github.io/100__2025_06_public/RAPORT/B_CRDL.TO_BAND.jpg' target='_blank'>    <img src='B_CRDL.TO_BAND.jpg' alt='B_CRDL.TO_BAND.jpg'></a></div></div></div>
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><div class='table-scroll'><table><tr><th>Date</th><th>Score</th><th>AMR</th><th>Type</th><th>Summary</th><th>Links</th></tr><tr class='pos-light'><td>2025-09-09</td><td>0.35</td><td></td><td>quarterly earnings</td><td>0.35 local feel              __   CRDL.TO __    -> i:0.35<-                      <br><br>FEELING: total score 0.35 Here's a breakdown of the scoring: Analyst Meetings: HC Wainwright initiated coverage with a "Buy" rating and a $9.00 price target (+0.1). Average analyst rating is Buy with a consensus price target of $8.00 (+0.05). Institutional investors accumulating shares: Suggests confidence (+0.1). Beat EPS estimate: Reported ($0.07) vs. ($0.11) expected (+0.05). Bank of America Corp DE increased position: (+0.05) Lion Street Advisors LLC boosted position: (+0.05) Phase II trial: The mention of Phase II trial results needing monitoring is a forward-looking event, but the lack of concrete news warrants a low score. (0) The negative stock price movement and low trading volume are considered backward-looking and have minimal impact on the overall score. The focus on anti-fibrotic and anti-inflammatory therapies is promotional language and receives a low score. --- <br> - Cardiol Therapeutics experienced a slight dip in stock price, but a Buy rating and $9.00 price target from HC Wainwright offer a potential upside. Institutional investors are accumulating shares, suggesting confidence, despite recent earnings slightly beating estimates. Monitor Phase II trial results for further clarity. <br><br>*** REZUMAT *** - Stock price down 3.7% to $1.05 on Monday, trading as low as $1.04. - Trading volume decreased by 71% to 338,307 shares. - HC Wainwright initiated coverage with a Buy rating and $9.00 price target. - Average analyst rating is Buy with a consensus price target of $8.00. - 50-day moving average: $1.26, 200-day moving average: $1.18. - Debt-to-equity ratio: 0.01, quick ratio: 2.46, current ratio: 2.46. - Market capitalization: $87.90 million, P/E ratio: -3.09, beta: 1.03. - Beat EPS estimate: reported ($0.07) vs. ($0.11) expected. - Bank of America Corp DE increased position by 136.2% to 26,455 shares. - Lion Street Advisors LLC boosted position by 8.5% to 333,725 shares. - Institutional ownership: 12.49% of outstanding shares. - Focuses on anti-fibrotic and anti-inflammatory therapies for heart diseases. - Lead product CardiolRx in Phase II trial for myocarditis and pericarditis.   (gemma3:12b-it-q4_K_M on 2025-09-09 20:16:26)</td><td><a href='https://www.defenseworld.net/2025/09/09/cardiol-therapeutics-nasdaqcrdl-trading-down-3-7-heres-why.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-05</td><td>0.30</td><td></td><td>Product launches</td><td>0.3 local feel              __   CRDL.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Breakdown: Product launches: (0.2 to +0.3) - The establishment of brain-specific PET scanning clinics represents a significant product launch, addressing a critical shortage and aligning with growing demand. The market projection for Alzheimer's therapeutics further supports the potential. Regulatory approvals: (0.0) - While the news mentions FDA-cleared PET scanners, this isn't a new approval but rather a confirmation of existing clearance. Strategic partnerships or joint ventures: (0.0) - No clear partnership is mentioned. Management changes: (0.0) - No management changes are mentioned. Analyst meetings: (0.0) - No analyst meetings are mentioned. Mergers/acquisitions: (0.0) - No mergers or acquisitions are mentioned. Capital raises: (0.0) - No capital raises are mentioned. Guidance updates: (0.0) - No guidance updates are mentioned. Share consolidations: (0.0) - No share consolidations are mentioned. Buyback programs: (0.0) - No buyback programs are mentioned. Lawsuits: (0.0) - No lawsuits are mentioned. Debt restructuring: (0.0) - No debt restructuring is mentioned. Credit rating changes: (0.0) - No credit rating changes are mentioned. Major political actions: (0.0) - No major political actions are mentioned. Regulatory changes: (0.0) - No regulatory changes are mentioned. Accretive to DCF per share: (0.0) - No explicit confirmation or modeling by analysts. Rationale: The news primarily focuses on a strategic shift and market opportunity. The establishment of PET scanning clinics and the projected growth in the Alzheimer's therapeutics market are positive indicators. However, the information is largely descriptive and doesn't contain specific financial commitments or projections that would warrant a higher score. The mention of existing FDA clearance and the equity stake in Seyltx are less impactful. --- <br> - Algernon Health's strategic shift into Alzheimer's diagnostics, coupled with favorable market trends and regulatory approvals, presents a compelling investment opportunity. The company's focus on specialized PET scanning clinics addresses a critical shortage and aligns with the growing demand for disease-modifying therapies. <br><br>*** REZUMAT *** - Algernon Pharmaceuticals rebrands to Algernon Health (AGN:CSE AGNPF:OTCQB AGW0:XFRA) focusing on Alzheimer's diagnostics. - Plans to establish brain-specific PET scanning clinics across North America. - FDA-cleared PET scanners offer lower radiation and are insured in the U.S. - Alzheimer's therapeutics market projected to grow from US$4.29B (2025) to US$10.43B (2035). - Demand driven by new drug approvals, investment in therapies, and precision medicine. - Shortage of PET scanners exists due to prioritization for cancer/cardiology. - Company retains 20% equity stake in Seyltx (Ifenprodil drug). - Management & insiders own ~11%, institutions ~21%, retail holds the rest. - Alpha North Asset Management is a top shareholder with 20.52%.   (gemma3:12b-it-q4_K_M on 2025-09-06 12:56:17)</td><td><a href='https://www.streetwisereports.com/article/2025/09/05/healthcare-firm-targets-alzheimers-with-technology-breakthrough.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-04</td><td>0.20</td><td></td><td>product launch</td><td>0.2 local feel              __   CRDL.TO __    -> i:0.2<-                      <br><br>FEELING: total score 0.2 Reasoning: The news primarily revolves around Cardiol Therapeutics aligning with Johnson & Johnson's focus on maternal fetal immunology and potential positive investor sentiment. This suggests a positive future prospect. Here's the breakdown based on the provided events: Product launches/Positive future prospects: +0.2 - The alignment with Johnson & Johnson's data and the emphasis on unmet needs suggests a potential positive future prospect for Cardiol's products, particularly given their focus on innovative medicine. This is a forward-looking statement. Analyst meetings: 0 - While the news might influence analysts, there's no explicit upgrade or downgrade mentioned. The news lacks specifics about financial performance, doesn't involve any negative events (lawsuits, debt restructuring, etc.), and is largely based on potential future alignment. Therefore, a moderate positive score is appropriate. --- <br> - Cardiol Therapeutics saw a premarket boost following Johnson & Johnson's data emphasizing unmet needs in maternal fetal immunology. This suggests potential alignment with Cardiol's focus and could signal positive future prospects for investors. <br><br>*** REZUMAT *** - Cardiol Therapeutics shares up 4.59% premarket. - Johnson & Johnson data highlights maternal fetal immunology needs. - ISUOG 2025 presentation emphasized unmet patient perspectives. - News aligns with Cardiol's focus on innovative medicine. - Potential for positive investor sentiment regarding Cardiol.   (gemma3:12b-it-q4_K_M on 2025-09-05 09:59:17)</td><td><a href='https://www.ainvest.com/news/cardiol-therapeutics-shares-rise-4-59-premarket-johnson-johnson-data-highlights-unmet-maternal-fetal-immunology-2509/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-19</td><td>0.30</td><td></td><td>quarterly earnings</td><td>event_TBD 0.30 GPT4 / 0.35 local feel              __   CRDL.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - HC Wainwright raised FY2028 earnings estimates and maintains a "Buy" rating with a $9.00 price target. New institutional investments and increased holdings by existing investors signal positive sentiment. Monitor Phase II trial results for CardiolRx. <br><br>*** REZUMAT *** - CRDL: HC Wainwright raised FY2028 earnings estimate to $0.51/share from $0.40. - Analyst B. Folkes maintains a "Buy" rating with a $9.00 price target. - CardiolRx is in Phase II trial for acute myocarditis and pericarditis. - Company reported ($0.07) EPS, beating estimate of ($0.11) on August 14. - Envestnet purchased $398,000 worth of shares in Q4. - Cetera Investment purchased $56,000 worth of shares in Q4. - PVG Asset Management purchased $624,000 worth of shares in Q4. - Lion Street Advisors increased holdings by 8.5% in Q1, owning 333,725 shares. - Tejara Capital increased holdings by 2.6% in Q1, owning 3,194,990 shares. - 12.49% of stock owned by institutional investors. - Market cap: $102.13 million.   <br> <br>-- GPT4: +0.3, Buy, Positive sentiment from raised earnings estimates and institutional investments suggests potential price increase.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-19 21:32:38)</td><td><a href='https://www.defenseworld.net/2025/08/19/equities-analysts-set-expectations-for-crdl-fy2028-earnings.html' target='_blank'>Link</a></td></tr><tr class='neg-mid'><td>2025-08-19</td><td>-0.70</td><td></td><td>quarterly earnings</td><td>-0.70 GPT4 / -0.30 local feel              __   CRDL.TO __    -> i:0.7<-                      <br><br>FEELING: -0.7 --- <br> - Cardiol Therapeutics reported Q2 2025 results with increased losses. Investors should carefully evaluate the company's path to profitability and future funding needs given the current financial performance. <br><br>*** REZUMAT *** - Q2 2025 financial results released. - Losses increased compared to previous periods. - Company facing challenges in achieving profitability. - Investors should monitor funding and future performance.   <br> <br>-- GPT4: -0.7, Hold, Increased losses suggest potential price decline; monitor closely.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-19 21:33:40)</td><td><a href='https://www.msn.com/en-us/money/savingandinvesting/cardiol-therapeutics-reports-q2-2025-financial-results-amid-rising-losses/ar-AA1Ky7Tq' target='_blank'>Link</a></td></tr></table></div></div>
    </div>
    </body>
    </html>
    